GlassScriptPhysician profile
Mary E Paquet
NPI 1235791369
$3,280.48
in general payments reported to CMS, 2019-2025
26 companies · $627 in 2025
The $627 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $431 · 2022: $324 · 2023: $614 · 2024: $1,285 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,525.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,309.57 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $218.72 | 2022-2024 | |
| Axsome Therapeutics, INC. | $197.12 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $187.95 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $146.60 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $113.27 | 2023-2025 | Trintellix |
| Glaxosmithkline, LLC. | $113.23 | 2021-2023 | Shingrix |
| Corium, LLC | $109.38 | 2023-2024 | Azstarys |
| Alkermes, INC. | $104.00 | 2024-2025 | Aristada, Lybalvi |
| Biohaven Pharmaceuticals, INC. | $101.49 | 2021 | |
| Lilly USA, LLC | $97.63 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $83.05 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.20 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $57.26 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $56.23 | 2024-2025 | Rexulti, Abilify Maintena |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $55.05 | 2023 | Phasix Mesh |
| Pfizer INC. | $51.64 | 2021 | |
| Currax Pharmaceuticals LLC | $43.44 | 2022-2025 | Contrave |
| Merck Sharp & Dohme LLC | $42.87 | 2021 | |
| Neurocrine Biosciences, INC. | $30.58 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.60 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.71 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.48 | 2023 | Farxiga |
| Lundbeck LLC | $17.86 | 2024 | Rexulti |
| Amneal Pharmaceuticals LLC | $15.55 | 2021 | |
| Genentech USA, INC. | $6.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Paquet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.